EXACT SCIENCES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-12-29: Form 8-K; Period of report 2025-12-23; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2025-11-20: Form 8-K; Period of report 2025-11-19; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2025-11-03: Form 8-K; Period of report 2025-11-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2025-08-06: Form 8-K; Period of report 2025-08-06; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-12-29 | 8-K | 2025-12-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously announced, on November 19, 2025, Exact Sciences Corporation, a Delaware corporation (“Exact”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Abbott Laboratories, an Illinois corporation (“Parent”), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which, among other things and subject to the conditions contained in the Merger Agreement, Merger Sub will merge with and into Exact, with Exact surviving as an indirect, wholly owned subsidiary of Parent. | d33273d8k.htm |
| 2025-11-20 | 8-K | 2025-11-19 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On November 20, 2025, Exact and Parent issued a joint press release announcing the execution of the Merger Agreement and the proposed transaction. | d38144d8k.htm |
| 2025-11-03 | 8-K | 2025-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2025, Exact Sciences Corporation (the "Company") announced its financial results for the quarter ended September 30, 2025. | exas-20251103.htm |
| 2025-08-06 | 8-K | 2025-08-06 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On August 6, 2025, Exact Sciences Corporation (the "Company") announced its financial results for the quarter ended June 30, 2025. 7.01 On August 6, 2025, the Company announced that it has entered into a Collaboration and License Agreement with Freenome Holdings, Inc. ("Freenome"), under which the Company and Freenome will collaborate to develop and commercialize certain blood-based screening and diagnostic products for colorectal cancer. | exas-20250806.htm |
| 2025-06-16 | 8-K | 2025-06-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 12, 2025, the shareholders of Exact Sciences Corporation (the “Company”) approved the adoption of the Company’s 2025 Omnibus Long-Term Incentive Plan (the “2025 Omnibus Plan”) at the 2025 Annual Meeting of Shareholders of the Company (the “2025 Annual Meeting”). 5.07 On June 12, 2025, the Company held its 2025 Annual Meeting. | exas-20250612.htm |
| 2025-05-01 | 8-K | 2025-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2025, Exact Sciences Corporation (the "Company") announced its financial results for the quarter ended March 31, 2025. | exas-20250501.htm |
| 2025-04-29 | 8-K | 2025-04-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 29, 2025, the Board of Directors (the “Board”) of Exact Sciences Corporation (the “Company”) appointed Leslie Trigg as a Class II member of the Board with a term ending at the Company’s 2026 annual meeting of shareholders. | exas-20250429.htm |
| 2025-02-19 | 8-K | 2025-02-19 | 2.02 Results of Operations and Financial Condition | exas-20250219.htm | |
| 2025-01-13 | 8-K | 2025-01-12 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 2.02 On January 12, 2025, the Company announced certain preliminary financial information for the quarter and full year ended December 31, 2024. 2.03 The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03. 7.01 The Company will post the PowerPoint presentation that the Company will present at the 2025 J.P. Morgan Healthcare Conference on January 13, 2025 to the Company's website, www.exactsciences.com, on the Events and Presentations page under the Investor Relations tab. | exas-20250112.htm |
| 2025-01-06 | 8-K | 2025-01-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 2, 2025, the Board of Directors (the “Board”) of Exact Sciences Corporation (the “Company”) expanded the size of the Board from nine to ten members and appointed Kim Popovits as a Class I member of the Board with a term ending at the Company’s 2025 annual meeting of shareholders. | exas-20250102.htm |